Advertisement

Picture Berlin Partner HealthCapital Bionnale 2018 Germany June 600x60px
Document › Details

Danaher Corporation. (3/7/18). "Press Release: Danaher Provides Update On First Quarter 2018 Financial Performance". Washington, DC.

Organisations Organisation Danaher Corporation (NYSE: DHR)
  Group Danaher (Group)
  Organisation 2 Cepheid (US) (Nasdaq: CPHD)
  Group Danaher (Group)
Products Product analytical instrument
  Product 2 laboratory equipment and instruments
Persons Person Joyce, Thomas P., Jr. (Tom) (Danaher 201503– promoted CEO before 25 years at Danaher)
  Person 2 Gugino, Matthew E. (Danaher 201407 VP Investor Relations)
     


Danaher Corporation (NYSE: DHR) (the "Company") announced today that it expects first quarter 2018 adjusted diluted net earnings per share to be above the high-end of the Company's previously communicated guidance range.

Thomas P. Joyce, Jr., President and Chief Executive Officer, stated, "We have seen a strong start to 2018 from both a core revenue and margin perspective and based on our results through February, we now expect first quarter 2018 adjusted EPS to be above the high-end of our previously communicated guidance range. Better than expected results in our Life Sciences and Diagnostics platforms – specifically at Cepheid – are the main drivers for this performance as we continue to see positive momentum in these businesses."

The Company will hold its quarterly earnings conference call for the first quarter 2018 on Thursday, April 19, 2018 at 8:00 a.m. ET.


ABOUT DANAHER

Danaher is a global science and technology innovator committed to helping its customers solve complex challenges and improving quality of life around the world. Its family of world class brands has leadership positions in some of the most demanding and attractive industries, including health care, environmental and industrial. With more than 20 operating companies, Danaher's globally diverse team of approximately 67,000 associates is united by a common culture and operating system, the Danaher Business System. For more information, please visit www.danaher.com.


FORWARD LOOKING STATEMENTS

Statements in this release that are not strictly historical, including the statements regarding the Company's anticipated first quarter 2018 adjusted diluted net earnings per share, core revenue growth and any other statements regarding events or developments that we believe or anticipate will or may occur in the future are "forward-looking" statements within the meaning of the federal securities laws. There are a number of important factors that could cause actual results, developments and business decisions to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. These factors include, among other things, deterioration of or instability in the economy, the markets we serve and the financial markets, contractions or growth rates and cyclicality of markets we serve, competition, our ability to develop and successfully market new products and technologies and expand into new markets, the potential for improper conduct by our employees, agents or business partners, our compliance with applicable laws and regulations (including regulations relating to medical devices and the health care industry), our ability to effectively address cost reductions and other changes in the health care industry, our ability to successfully identify and consummate appropriate acquisitions and strategic investments and successfully complete divestitures and other dispositions, our ability to integrate the businesses we acquire and achieve the anticipated benefits of such acquisitions, contingent liabilities relating to acquisitions, investments and divestitures (including tax-related and other contingent liabilities relating to the distributions of each of Fortive Corporation and our communications business), security breaches or other disruptions of our information technology systems or violations of data privacy laws, the impact of our restructuring activities on our ability to grow, risks relating to potential impairment of goodwill and other intangible assets, currency exchange rates, tax audits and changes in our tax rate and income tax liabilities, changes in tax laws applicable to multinational companies, litigation and other contingent liabilities including intellectual property and environmental, health and safety matters, the rights of the United States government to use, disclose and license certain intellectual property we license if we fail to commercialize it, risks relating to product, service or software defects, product liability and recalls, risks relating to product manufacturing, the impact of our debt obligations on our operations and liquidity, our relationships with and the performance of our channel partners, uncertainties relating to collaboration arrangements with third parties, commodity costs and surcharges, our ability to adjust purchases and manufacturing capacity to reflect market conditions, reliance on sole sources of supply, the impact of deregulation on demand for our products and services, labor matters, international economic, political, legal, compliance and business factors (including the impact of the UK's decision to leave the EU and changes in U.S. policy stemming from the current administration, such as changes in trade policy), disruptions relating to man-made and natural disasters, and pension plan costs. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in our SEC filings, including our 2017 Annual Report on Form 10-K. These forward-looking statements speak only as of the date of this release and except to the extent required by applicable law, the Company does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise.


For further information:
Matthew E. Gugino, Vice President, Investor Relations, Danaher Corporation, 2200 Pennsylvania Avenue, N.W., Suite 800W, Washington, D.C. 20037, Telephone: (202) 828-0850, Fax: (202) 828-0860

   
Record changed: 2018-03-27

Advertisement

Picture Berlin Partner HealthCapital Bionnale 2018 June Matchmaking 600x60px

More documents for Danaher (Group)


To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com

Advertisement

Picture EBD Group ChinaBio Partnering Forum 2018 Suzhou CBPF April 600x60px




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture EBD Group ChinaBio Partnering Forum 2018 Suzhou CBPF April 120x180px Picture Berlin Partner HealthCapital Bionnale 2018 June Matchmaking 120x240px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture Berlin Partner HealthCapital Bionnale 2018 Germany June 120x240px Picture EBD Group ChinaBio Partnering Forum 2018 Suzhou CBPF April 120x180px